[Aortic valve replacement with a Cryolife O'Brien stentless bioprosthesis].
OBJECTIVE
The Cryolife O'Brien xenograft is a stentless bioprosthesis constructed from noncoronary leaflets from three porcine aortic valves. The aim of this study was to investigate short-term results after aortic valve replacement with this composite xenograft.


METHODS
Since October 1993, Cryolife O'Brien bioprostheses have been implanted in 210 patients. The patients' mean age was 70.9 (7.5) years (range 23-83 years). The indication was aortic stenosis in 132 cases, aortic insufficiency in 25 cases, and both lesions in 53 cases. Valve function was studied by echocardiography preoperatively, at discharge, and 6 and 12 months postoperatively.


RESULTS
The 30-day mortality rate was 5.2% (11/210). Over time, the mean gradients decreased and the effective area index increased. In addition, the left ventricular mass index, wall thickness, and septum thickness also decreased shortly after surgery.


CONCLUSIONS
Use of the Cryolife O'Brien stentless bioprosthesis demonstrated satisfactory results at 1-year follow-up. Additional follow-up is required to assess the performance of this bioprosthesis over the long term.
Campos
Vicente
V
Servicio de Cirugía Cardiaca, Hospital Universitario Juan Canalejo, A Coruña, Spain. vcampos@ya.com
Adrio
Belén
B
Estévez
Francisco
F
Mosquera
Víctor X
VX
Pérez
Javier
J
Cuenca
José J
JJ
Herrera
José M
JM
Valle
José V
JV
Portela
Francisco
F
Rodríguez
Fernando
F
Juffé
Alberto
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001022:Aortic Valve Insufficiency / Q000401:mortality / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000401:mortality / Q000601:surgery*; D001705:Bioprosthesis; D002423:Cause of Death; D005260:Female; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000401:mortality; D017052:Hospital Mortality; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D015996:Survival Rate